BioCentury
ARTICLE | Company News

Takeda sales and marketing update

February 13, 2012 8:00 AM UTC

Takeda launched Edarbyclor azilsartan medoxomil/chlorthalidone in the U.S. to treat hypertension. Edarbyclor is a fixed-dose combination of azilsartan, an angiotensin II type 1 (AT1) receptor blocke...